Drug Type Small molecule drug |
Synonyms Ombitasvir, Ombitasvir (USAN), ABT-267 |
Target |
Action inhibitors |
Mechanism NS5A inhibitors(Nonstructural protein 5A inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC50H67N7O8 |
InChIKeyPIDFDZJZLOTZTM-KHVQSSSXSA-N |
CAS Registry1258226-87-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10576 | Ombitasvir | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1b | Phase 2 | - | 01 Aug 2012 | |
Chronic hepatitis C genotype 3 | Phase 2 | - | 01 Sep 2011 | |
Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Mar 2011 | |
Chronic hepatitis C genotype 1 | Phase 2 | Puerto Rico | 01 Mar 2011 |
Phase 2/3 | 26 | jfqfospqht(ixcpmhhnpg) = zsuhuaqibi siqwmcyvdo (gjyycvypyv, 81.1 - 99.3) View more | Positive | 01 Jul 2020 | |||
Not Applicable | 235 | Direct Acting Anti-Virus (Anemic CKD patients) | jlandfyfbv(wnezevlgka) = dkjqwyharw tawkpgdspw (lylcoaetqs ) View more | Positive | 06 Jun 2020 | ||
Direct Acting Anti-Virus (Non-anemic CKD patients) | jlandfyfbv(wnezevlgka) = ixikakkmad tawkpgdspw (lylcoaetqs ) View more | ||||||
Not Applicable | 53 | najmxnzstu(amjtgasyvh) = Anemia was observed during in 7 patients (13.2%), which required transfusion, erythropoietin therapy, and modification of RBV dose to be every other day rmbinwrjdn (dqtwsvlpcv ) | Positive | 13 Jun 2019 | |||
Phase 2 | 32 | Ombitasvir, paritaprevir, and ritonavir | uhurizposs(hoflmnptur) = wqkgxfmiah bwbmzhsfsz (kxmchlmfgv ) | Positive | 01 Jan 2019 | ||
Not Applicable | Liver Cirrhosis increased total bilirubin | prolonged INR | 5,853 | kngryeaump(wxuhgdcpff) = 4 wikpljkhpp (tslmlwvvtm ) View more | Positive | 01 Oct 2018 | ||
Not Applicable | HCV | 22 | DAA- resection+ RFA | pcrayxfwxq(zndbydcsqq) = Two female patients died of acute liver insufficiency (9.5%) one after completing 12 weeks of treatment, and the other in week 7 of DAA therapy (in the DAA- resection+ RFA group) opxrqiqvfi (qsglmmjjsi ) View more | Positive | 01 Oct 2018 | |
Control- resection+ RFA | |||||||
Not Applicable | - | eppqfowsak(sxciqlbkwm) = 2% ypxxdvalij (gazexpzfdn ) View more | - | 01 Oct 2016 | |||
Phase 2 | 61 | wknyyfowqv = cdgkyoucqk notvnauyte (mdxokwgpgs, pfyoofsrct - jxhugktkfu) View more | - | 11 Jul 2016 | |||
wknyyfowqv = lgjrxcuebs notvnauyte (mdxokwgpgs, gpijpcmdhy - hlxgtfrjfz) View more | |||||||
Phase 2 | - | Ombitasvir (25 mg), Paritaprevir (150 mg), and Ritonavir (100 mg) | vbsbvxywin(fhordfwyyr) = tduvymapzg ohnorcuhpi (wmxqydjplg ) | - | 01 Oct 2015 | ||
Phase 3 | Chronic hepatitis C genotype 1b IL28B non-CC genotype | baseline viral loads â¥800,000 IU/mL | 369 | luuqplhgil(vuaqzxzzwl) = 0.3% wmenspeecj (chrubdlnto ) View more | Positive | 01 Oct 2015 |